Financial Performance - The net loss for the six months ended June 30, 2021, was $34.8 million, compared to a net loss of $18.7 million for the same period in 2020[144]. - For the six months ended June 30, 2021, net revenues were $1.301 million, an increase from $0 in the same period in 2020[176]. - The net loss for the six months ended June 30, 2021, was $34.765 million, compared to a net loss of $18.709 million for the same period in 2020, reflecting an increase in loss of $16.056 million[176]. - Total operating expenses for the six months ended June 30, 2021, were $31.868 million, up from $17.656 million in the same period in 2020, representing an increase of $14.212 million[176]. - Selling and marketing expenses for the six months ended June 30, 2021, totaled $20.877 million, a rise of $15.985 million, or 327%, from $4.892 million in the same period in 2020[180]. Research and Development - The company incurred research and development expenses of $13.5 million, $9.9 million, and $9.8 million for the years ended December 31, 2020, 2019, and 2018, respectively[138]. - For the three months ended June 30, 2021, research and development expenses were approximately $0.9 million, down from $3.7 million for the same period in 2020[157]. - Research and development expenses decreased by $2.799 million, or 76%, from $3.661 million in Q2 2020 to $0.862 million in Q2 2021[172]. - Research and development expenses for the six months ended June 30, 2021, were $2.975 million, a decrease of $3.850 million, or 56%, from $6.825 million in the same period in 2020[177]. - Approximately 29% of the product sold during the six months ended June 30, 2021, consisted of validation inventory previously expensed as research and development in Q4 2020[177]. Cash and Liquidity - The company had cash, cash equivalents, and marketable securities of $31.1 million as of June 30, 2021, compared to $54.5 million as of December 31, 2020[139]. - Net cash used in operating activities was $30.0 million for the six months ended June 30, 2021, primarily due to a net loss of $34.8 million[185]. - Net cash provided by investing activities for the six months ended June 30, 2021 was $34.6 million, primarily from net sales and maturities of marketable securities[189]. - Net cash provided by financing activities for the six months ended June 30, 2021 was $7.1 million, consisting of net proceeds of $7.0 million from the sale of 5,113,971 shares of common stock[190]. - The company plans to monitor its liquidity closely and may revise its commercial plans if the COVID-19 pandemic impacts its ability to generate revenue[142]. Commercialization Efforts - The company plans to continue its commercialization efforts for Twirla, focusing on expanding coverage and reimbursement in the U.S.[133]. - The company expects to continue incurring significant operating expenses to support the commercialization of Twirla and evaluate additional product candidates[192]. - As of June 30, 2021, the company committed $7.1 million for purchases under the Manufacturing and Commercialization Agreement with Corium, Inc.[193]. Capital and Financing - A public offering in February 2020 raised approximately $48.4 million from the sale of 17,250,000 shares at $3.00 per share[141]. - The company entered into a Credit Agreement for a senior secured term loan credit facility of up to $35.0 million, with additional tranches available upon achieving revenue milestones[140]. - The company plans to monitor its liquidity to ensure adequate funding for operations, with a potential to access up to $200.0 million through the 2020 Shelf Registration Statement[191]. Operational Challenges - The company recognizes substantial doubt about its ability to continue as a going concern through the next 12 months due to its reliance on raising additional capital[147]. - The company does not believe inflation had a material effect on its business during the six months ended June 30, 2021[207].

Agile Therapeutics, Inc. (OTCQB:AGRX) Q1 2021 Earnings Conference Call May 4, 2021 4:30 PM ET Company Participants Matthew Riley - Head, IR & Corporate Communications Alfred Altomari - Chairman & CEO Dennis Reilly - SVP & CFO Conference Call Participants Oren Livnat - H.C. Wainwright & Co. Leland Gershell - Oppenheimer Timothy Lugo - William Blair & Company Nazibur Rahman - Maxim Group Operator Good afternoon, and welcome to the Agile Therapeutics' First Quarter 2021 Financial Results Conference Call. Pleas ...

Agile Therapeutics, Inc. (OTCQB:AGRX) Q4 2020 Earnings Conference Call March 1, 2021 4:30 PM ET Company Participants Matthew Riley - Investor Relations Alfred Altomari - Chairman, President & Chief Executive Officer Dennis Reilly - Senior Vice President & Chief Financial Officer Conference Call Participants Oren Livnat - H.C. Wainwright Leland Gershell - Oppenheimer Lachlan Hanbury-Brown - William Blair & Company Operator Ladies and gentlemen, thanks for standing by, and welcome to the Agile Therapeutics Fo ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36464 Agile Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2936302 (State or other jurisdictio ...

Agile Therapeutics, Inc. (OTCQB:AGRX) Q3 2020 Earnings Conference Call November 12, 2020 4:30 PM ET Company Participants Matthew Riley - Investor Relations Alfred Altomari - Chairman, President & Chief Executive Officer Dennis Reilly - Senior Vice President & Chief Financial Officer Conference Call Participants Randall Stanicky - RBC Capital Markets Oren Livnat - H.C. Wainwright Timothy Lugo - William Blair & Company Leland Gershell - Oppenheimer Paul Biedlingmaier - Edward Jones Operator Good afternoon and ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36464 Agile Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2936302 (State or o ...

Agile Therapeutics, Inc. (OTCQB:AGRX) Q2 2020 Earnings Conference Call August 11, 2020 4:30 PM ET Company Participants Matthew Riley - Investor Relations Alfred Altomari - Chairman, President & Chief Executive Officer Dennis Reilly - Senior Vice President & Chief Financial Officer Conference Call Participants Daniel Busby - RBC Capital Markets Timothy Lugo - William Blair & Company Leland Gershell - Oppenheimer Oren Livnat - H.C. Wainwright Operator Greetings and welcome to the Agile Therapeutics Second Qua ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36464 Agile Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 23-2936302 (State or other ...